Minimizing Patient Risks From COVID-19

This activity is jointly provided by Global Education Group and Integritas Communications.

This educational activity is supported by an educational grant from GlaxoSmithKline.

This is an affiliated event (not official IDWeek programming).

Target Audience

This program is intended to educate infectious disease, internal medicine, and other clinicians involved in the management of patients with mild or moderate coronavirus disease 2019 (COVID-19) who are at risk for clinical progression.

Program Description

As the COVID-19 pandemic continues to be an overwhelming public health concern around the world, there is also rapid progress in both treatment and prevention. Multiple anti-SARS-CoV-2 monoclonal antibodies (mAbs) have gained Emergency Use Authorization (EUA) from the US Food and Drug Administration, though clinicians and patients alike have questions about safety, efficacy, eligibility, access, and implementation. A panel of experts will present data on and discuss current evidence and regulatory status for these anti-SARS-CoV-2 mAbs, updates to National Institutes of Health guidelines on patient identification and stratification, implementation, and strategies to reduce health care disparities. Patient-clinician interactions will be included to provide examples of optimal communication.

Educational Objectives

After completing the activity, participants will be better prepared to:

1. Discuss the clinical profiles and trial data for current and emerging anti-SARS-CoV-2 mAbs
2. Assess patients with COVID-19 who are at high risk for clinical progression, hospitalization, and other poor outcomes
3. Manage patients with COVID-19 who qualify for anti-SARS-CoV-2 monoclonal antibody therapy based on current guidelines from the US Food and Drug Administration
4. Address barriers to the use of anti-SARS-CoV-2 monoclonal antibody therapies, including patient reluctance and healthcare disparities

Agenda

11:00–11:05 AM Preactivity Questionnaire and Faculty Introductions
11:05–11:30 AM Clinical Trial And EUA Status of Anti-SARS-CoV-2 Monoclonal Antibodies
11:30–11:50 AM Identifying Patients to Be Treated With Anti-SARS-CoV-2 Monoclonal Antibodies
11:50–12:15 PM Treating Patients With Anti-SARS-CoV-2 Monoclonal Antibodies in Real-World Practice
12:15–12:40 PM Addressing Disparities in Patient Use of Anti-SARS-CoV-2 Monoclonal Antibodies
12:40–1:00 PM Postactivity Questionnaire and Q&A Session

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-280-L01-P)

This is a knowledge-based activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 2.0 contact hour(s) (which includes * hour(s) of pharmacology).

*Pharmacology hour(s) to be determined after clinical content review.

Instructions to Receive Credit

Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days after participating in the activity. Pharmacist learners must check the CPE monitor within 60 days of the activity for their credit.

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this workshop, please contact Integritas Communications at info@exchangecme.com.